PHARVARIS NV

Pharvaris CEO Modig sells 2,292 shares at €34.97 under a 10‑b‑5 plan, a routine move that signals liquidity management amid a strong growth pipeline and positive market sentiment.

Pharvaris NV insiders sell shares amid strong Phase IIb data for an oral β2‑receptor antagonist, and EMA’s provisional approval signals a promising future for chronic respiratory therapy.

Pharvaris insider sales trend: CEO Modig’s routine June 2,191‑share sale shows disciplined liquidity management, not a signal of strategic shift, but a possible take‑profit trend for investors to watch.

Pharvaris insider sales show routine liquidity moves, not loss of confidence—evaluate the clinical‑stage B2 antagonist pipeline for long‑term upside.

Pharvaris NV insider trades reveal a strategic mix of buying at €8.05, selling at €29.32 and holding 25,167 shares—showing confidence in β2‑antagonist breakthroughs and market momentum.

Pharvaris NV insider trading reveals CEO liquidity moves—yet the firm’s strong B2 antagonist pipeline and outcome‑based pricing strategy keep long‑term prospects bright.

Pharvaris NV insiders buy at discount, sell at premium and liquidate options—showing bullish confidence in its B₂‑receptor pain drugs and upcoming regulatory approvals.

Pharvaris insider sale sparks debate: learn how a routine 109‑share sell reflects confidence amid strong rally, regulatory milestones, and extended‑release innovation.

Pharvaris insider sales show routine liquidity moves, not a sign of confidence, as the stock keeps rising on solid earnings and a strong B2‑receptor pipeline.

Pharvaris insider trades show confidence in its oral B2 antagonist pipeline for fibrosis, with Lu Peng buying low, selling high, and signaling a steady upside.